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ABSTRACT 16 
Prior genome-wide association studies have identified a melanoma-associated locus on 17 
chr1q42.1 that encompasses a ~100 kb region spanning the PARP1 gene. eQTL analysis in 18 
multiple cell types of melanocytic lineage consistently demonstrated that the 1q42.1 melanoma 19 
risk allele (rs3219090, G) is correlated with higher PARP1 levels. In silico fine-mapping and 20 
functional validation identified a common intronic indel, rs144361550 (-/GGGCCC, r2 =0.947 21 
with rs3219090) as displaying allele-specific transcriptional activity. A proteomic screen 22 
identified RECQL as binding to rs144361550 in an allele-preferential manner. In human primary 23 
melanocytes, PARP1 promotes cell proliferation and rescues BRAFV600E-induced senescence 24 
phenotypes in a PARylation-independent manner. PARP1 also transforms TERT-immortalized 25 
melanocytes expressing BRAFV600E. PARP1-mediated senescence rescue is accompanied by 26 
transcriptional activation of melanocyte lineage survival oncogene, MITF, highlighting a new role 27 
of PARP1 in melanomagenesis. 28 
 29 
To date, genome-wide association studies (GWAS) have identified twenty common, 30 
genome-wide significant melanoma susceptibility loci1-9, most of which do not appear to be 31 
explained by protein-coding variants.  A subset of these loci harbor known pigmentation genes 32 
that mediate melanoma-associated phenotypes such as eye, hair, and skin color.  While several 33 
loci harbor genes implicated in cancer, evidence directly linking common risk variants within 34 
most of these loci to altered function of specific genes is lacking. 35 
MacGregor and colleagues initially identified a melanoma risk locus tagged by 36 
rs3219090 on chromosome band 1q42.1 in an Australian case-control study at a near genome-37 
wide level of significance (P = 9.3 x 10-8 , OR = 0.87, protective allele A)8.  The association has 38 
since been replicated by multiple other studies3,10, including most recently by a meta-analysis of 39 
12,874 melanoma cases (rs1858550, P = 1.7 x 10-13)7.  Notably, the locus at 1q42.1 has also 40 
been associated with melanoma survival11, where the melanoma risk allele correlates with 41 
increased survival, an association that has since been replicated12. The region of association 42 
spans from 226.52 Mb to 226.63 Mb (hg19) of chromosome 1, encompassing the entirety of the 43 
poly(ADP-ribose) (PAR) polymerase-1 (PARP1) (OMIM: 173870) gene, and fine-mapping 44 
suggests that the association is best explained by a single-SNP model3.   45 
While a number of other genes are located in the vicinity of the association peak, PARP1 46 
has the most well-established role in cancer.  PARP1 is best known for its role as a DNA repair 47 
enzyme and genotoxic sensor that functions in base excision repair (BER), single-strand break 48 
repair, and double-strand break repair13.  Once PARP1 binds to damaged DNA, its enzymatic 49 
function is activated, and it covalently attaches PAR polymers to acceptor proteins, including 50 
histones and PARP1 itself14. PARP1 amplifies DNA damage signals, modifies chromatin 51 
structures to accommodate DNA damage response proteins, and further recruits DNA repair 52 
proteins13,15,16.  While PARP1 is not directly involved in repair of UV signature mutations via 53 
nucleotide excision repair, its role in the repair of DNA lesions induced by reactive oxygen 54 
species (ROS) is well-established17. ROS are generated by UVA exposure18, are a byproduct of 55 
melanin production19, and appear to play a role in oncogene-induced senescence (OIS)20,21.  56 
Aside from DNA repair, PARP1 functions in regulating gene expression by modifying chromatin 57 
structure, associating with promoters and enhancers, and acting as a transcriptional co-58 
regulator22,23.  While many of these roles rely on PARP1 catalytic activity, some are also 59 
PARylation-independent, as in the transcriptional co-regulator function for NF-kB and B-60 
MYB24,25. 61 
In this study, we functionally characterized the 1q41.2 melanoma risk locus, 62 
demonstrating a consistent correlation of the risk genotype with levels of PARP1 gene 63 
expression in tissues of melanocytic origin, identifying a gene regulatory variant within the first 64 
intron of PARP1, and elucidating a role for PARP1 in melanocyte OIS via regulation of the 65 
melanocyte master regulatory transcription factor, MITF. 66 
 67 
RESULT 68 
The rs3219090 risk allele is correlated with high PARP1 69 
We performed expression quantitative trait locus (eQTL) analysis in order to identify 70 
genes for which expression levels are correlated with 1q42.1 risk genotype in tissues of 71 
melanocytic lineage.  Initially we evaluated the correlation of rs3219090 with expression of 72 
genes within +/-1Mb in 59 early-passage melanoma cell lines using expression microarray data. 73 
The results indicated that the rs3219090 risk allele is associated with higher levels of PARP1 74 
expression (P = 1.4 x 10-3, linear regression; Fig. 1a). Notably, PARP1 is the only gene in the 75 
region that passed a Bonferroni-corrected P-value threshold (corrected for 14 genes, P < 3.6 x 76 
10-3; Supplementary Table 1), and this eQTL subsequently validated via qPCR assay (P = 77 
0.031, linear regression; Supplementary Fig. 1a).  We then sought independent replication of 78 
PARP1 and other nominally significant eQTL genes (P < 0.05) in publicly available RNA-79 
sequencing datasets for melanoma-relevant tissues. When 409 melanoma tumors from The 80 
Cancer Genome Atlas (TCGA) project (dbGAP Accession: phs000178.v9.p8) were tested, the 81 
melanoma risk allele of rs3219090 was again significantly correlated with higher PARP1 82 
expression levels (P = 3.9 x 10-3, linear regression using copy number as a covariate; 83 
Supplementary Fig. 1b) while no other genes were significantly correlated (Supplementary 84 
Table 2). Similarly, the PARP1 eQTL was replicated in normal skin samples collected through 85 
the Genotype-Tissue Expression (GTEx) Project (dbGAP Accession: phs000424.v6.p1), 86 
including those derived from both sun-exposed skin (P = 2 x 10-4, linear regression, n = 302) 87 
and non-sun-exposed skin (P = 0.011, linear regression, n = 196) (Supplementary Fig 1c-d, 88 
Supplementary Table 3-4). Together, these data identified PARP1 as the strongest eQTL gene 89 
in the chr1q42.1 locus whose expression displayed the most consistent correlation with 90 
genotypes of the lead SNP in sample panels of melanocytic lineage as well as human skin.    91 
To complement eQTL data and rule out the possibility of any sample-specific 92 
confounding factors masking genotype effect, we performed allele-specific expression (ASE) 93 
analysis for PARP1 in samples carrying both risk and protective alleles. Fourteen melanoma cell 94 
lines that are heterozygous for rs3219090 and harbor normal regional copy number were 95 
assayed using a quantitative allelic TaqMan assay for a synonymous coding surrogate SNP 96 
(rs1805414; r2 = 0.98 with rs3219090 in 1KG phase3 EUR), where allelic ratio was inferred from 97 
known ratios of allelic standards. The results demonstrated a significant allelic imbalance 98 
towards a higher proportion of PARP1 expressed from the risk allele in the majority of 99 
heterozygous cell lines (P = 1.2 x 10-4, two-tailed Wilcoxon signed rank test; Fig. 1b). Significant 100 
allelic imbalance was also observed when a subset of these cell lines were analyzed by 101 
RNAseq (data not shown). Subsequent PARP1 ASE analysis in TCGA and GTEx RNAseq 102 
datasets demonstrated that a higher allelic proportion of mapped reads was also observed for 103 
the risk allele across TCGA tumor samples (P = 0.011, two-tailed Wilcoxon signed rank test, n = 104 
48, copy-neutral and heterozygous; Fig. 1c), as well as in sun-exposed and non-sun-exposed 105 
skin tissues (GTEx, P = 1.16 x10-5, n = 139; P = 8.9 x 10-5, n = 69; respectively, two-tailed 106 
Wilcoxon signed rank test; Supplementary Fig. 1e-f). These data demonstrate that the 107 
melanoma risk allele of rs3219090 is significantly associated with increased PARP1 expression 108 
in tissues of melanocytic origin and skin with striking consistency across multiple datasets.  109 
 110 
Fine-mapping and functional annotation of candidate SNPs 111 
Given that high PARP1 levels are correlated with the melanoma risk allele of rs3219090, 112 
we next sought to identify functional risk variant(s) that may influence PARP1 expression.  113 
Previously, fine-mapping of this locus in a large European population provided support for a 114 
model in which a single variant accounts for the association signal in this region3, a finding 115 
confirmed as part of the meta-analysis conducted by Law and colleagues7.  We prioritized 65 116 
variants that are highly correlated with the lead SNP as candidate functional variants (r2>0.6 117 
with lead SNPs from the discovery or meta-analysis lead SNPs3,7, rs3219090 and rs1858550, 118 
respectively; LD based on 1KG phase3, EUR and CEU).  Given the absence of amino acid-119 
changing PARP1 variants within this set of candidates, an absence of evidence for alternative 120 
splicing as a likely mechanism (Supplementary Note), and considerable evidence for allelic 121 
differences in PARP1 expression levels, we focused on those located within annotated 122 
melanocyte- or melanoma-specific cis-regulatory elements using data from the ENCODE26 and 123 
Roadmap projects27 (Supplementary Note, Supplementary Table 5-6, Supplementary Fig. 124 
2-3). The four of the most strongly supported variants are situated at the center of melanocyte 125 
DHS peaks as well as within regions harboring promoter or enhancer histone marks (H3K4me1, 126 
H3K4me3, or H3K27ac) in the majority of melanocyte/melanoma cultures assayed 127 
(Supplementary Table 6).  Based on these data, we proceeded with functional characterization 128 
of these four candidates (Supplementary Table 6, Supplementary Fig. 2).  129 
 130 
An intronic indel displays allelic transcriptional activity 131 
We assessed all four candidate functional variants for gene regulatory potential using 132 
luciferase reporter assays, as well as for allelic patterns of protein binding via electrophoretic 133 
mobility shift assay (EMSA). For these assays, we sought to identify variants that display 1) 134 
transcriptional activation consistent with ENCODE annotation, 2) higher activity for the risk allele 135 
consistent with the eQTL data, and 3) allele-specific protein binding. Among four candidate 136 
variants, only rs144361550, a GGGCCC indel variant, met all these criteria (Fig. 2-3, 137 
Supplementary Figs. 4-6; summarized in Supplementary Table 7). Namely, luciferase assays 138 
conducted in a melanoma cell line demonstrated that the genomic region around rs144361550 139 
exhibits strong transcriptional activity in both long (905bp covering the larger DHS region, ~17-140 
20 fold higher than control levels) and short cloned fragments (22 or 28bp covering the 141 
GGGCCC repeats, ~1.7-2.5 fold higher than control levels; Fig. 3a), where the risk-associated 142 
deletion allele exhibited higher reporter activity than the insertion allele (30-45% higher). In 143 
primary melanocytes, where transfection efficiency is considerably lower, allelic activity was not 144 
observed, but the long deletion and insertion fragments displayed weak but significant 145 
transcriptional activity (P = 1.2 x 10-3 and 5.9 x10-4, respectively, two-tailed, paired t-test; Fig. 146 
3c). EMSAs using nuclear extract from melanoma cell lines or cultured primary human 147 
melanocytes displayed preferential binding of nuclear proteins to the insertion allele (Fig. 3b,d). 148 
Given the potential for miscalling genotype of this functional indel, we directly genotyped 149 
rs144361550 in a large reference set to confirm LD with the lead SNP (Supplementary Note, 150 
Supplementary Table 8-9, Supplementary Fig. 7-8).  151 
To identify proteins that bind rs144361550 in an allele-preferential manner, we utilized 152 
quantitative mass-spectrometry employing dimethyl label swapping28,29 30.  Mass-spectrometry 153 
using melanoma cell line extract identified exclusively insertion allele-preferential interactors, the 154 
majority of which are not conventional transcription factors, including the RECQL helicase (Fig. 155 
4a). While two transcription factors previously found by the ENCODE Project to localize to the 156 
region overlapping rs144361550 via chromatin immunoprecipitation (ChIP) were found to bind 157 
rs144361550 probes (TFAP2A, ZBTB7A), neither did so in an allele-preferential manner (data 158 
not shown), in line with the observation that rs144361550 creates no new sequence motifs but 159 
rather extends a poly-G repeat stretch. We then performed a series of antibody supershifts and 160 
EMSAs using purified recombinant proteins for multiple candidates and validated that RECQL is 161 
an unequivocal allele-preferential binder to rs144361550 (Fig. 4b, Supplementary Figs. 9, and 162 
Supplementary Table 10). ChIP assays indicated that RECQL indeed binds to the PARP1 163 
indel region in melanoma cells and primary human melanocytes carrying an insertion allele (Fig. 164 
4c, Supplementary Fig. 10). We also performed a series of in silico and in vivo assays testing 165 
for alternative DNA secondary structure formation (G-quadruplex or G4), with the results 166 
suggesting RECQL-specific allelic binding mechanism rather than the one through G4 167 
(Supplementary Note, Supplementary Table 10-11, Supplementary Fig. 11-13). 168 
Ectopic expression of RECQL in three melanoma cell lines carrying insertion or deletion 169 
alleles at a moderate level using lentiviral transduction resulted in a mild increase in PARP1 170 
transcription (Fig. 4d). We then performed luciferase assays for rs144361550 with or without 171 
RECQL over-expression in cells with low baseline levels of RECQL relative to melanomas 172 
(HEK293FT cells). At a basal level, insertion and deletion alleles did not display differential 173 
luciferase activity, but upon RECQL over-expression, significant allele-specific transcriptional 174 
activity we previously observed in melanoma cell lines was recapitulated (Fig. 4e). Together, 175 
these data suggest that RECQL may play a role in PARP1 allelic expression in cells of 176 
melanocytic lineage through the melanoma risk-associated indel, rs144361550. 177 
 178 
PARP1 facilitates melanocyte growth and transformation 179 
Given that the risk allele of rs3219090 is associated with increased levels of PARP1 180 
expression, we tested whether increased PARP1 levels could lead to altered cellular 181 
phenotypes relevant to melanomagenesis. As BRAFV600E -induced senescence is well accepted 182 
as a barrier to malignant transformation in early events of melanomagenesis 31-33 and ROS 183 
seems to present a potential functional link between PARP1 and OIS 21, we examined whether 184 
elevated PARP1 modulates OIS by overexpressing PARP1 in human primary melanocytes 185 
expressing oncogenic BRAF (BRAFV600E). Consistent with published results, ectopic expression 186 
of BRAFV600E in human melanocytes induced a robust arrest of cell growth and proliferation, 187 
accompanied by heterochromatic H3K9Me3 focus formation (Fig. 5a-c, Supplementary 188 
Fig.14), DQGDPRGHUDWHLQFUHDVHLQȕ-galactosidase activity (Supplementary Fig. 15), both 189 
hallmarks of OIS. Overexpression of PARP1 prior to induction of BRAFV600E, however, 190 
prevented the cell cycle arrest and H3K9Me3 focus formation DVZHOODVȕ-galactosidase activity 191 
observed in melanocytes expressing BRAFV600E alone (Fig. 5a-c, Supplementary Fig. 14-15), 192 
demonstrating a rescue from BRAFV600E-induced senescence. Crystal violet staining of cells 193 
three weeks following PARP1 expression indicated that PARP1 by itself can also increase cell 194 
proliferation in the absence of BRAFV600E, suggesting an effect on cell proliferation by PARP1 195 
(Fig. 5a). PARP1 consistently exerted weak but significant effects on cell proliferation and OIS 196 
reversal even at a moderate induction level (~1.5 fold, Supplementary Fig. 16) recapitulating 197 
the subtle allelic expression differences observed in melanomas carrying risk or protective 198 
alleles. Several oncogenes, including MYC 34 and PIK3CA 33, have been reported to stimulate 199 
malignant transformation in melanoma cells by abrogating OIS and restarting cell proliferation. 200 
To further evaluate if PARP1 can stimulate malignant transformation by affecting melanocyte 201 
proliferation, we examined the effect of PARP1 on anchorage-independent growth of TERT-202 
immortalizHGKXPDQPHODQRF\WHVS¶PHO35) by soft-agar assay. PARP1 cooperated with 203 
BRAFV600E to enhance colony formation of S¶PHOFHOOVLQVRIWDJDUVLPLODUWRWKHSUHYLRXVO\204 
reported effect of MITF35, albeit to a lesser degree (Fig. 5d-e). Thus, like deregulated MITF 205 
expression, increased expression of PARP1 can both rescue and further transform human 206 
melanocytes from BRAFV600E-induced senescence.  207 
Most of the well-characterized functions of PARP1, including those involving DNA repair, 208 
are closely linked to its poly-ADP ribosylation activity. We therefore tested whether PARP1-209 
mediated rescue of melanocytes from BRAFV600E-induced OIS is dependent on PARP1 catalytic 210 
activity. Melanocytes overexpressing both PARP1 and BRAFV600E were treated with the PARP1 211 
inhibitor BYK20416536, and the inhibition of PAR-activity was confirmed by Western blotting with 212 
an antibody recognizing PAR (Fig. 6a). BYK204165 treatment did not block the cell proliferation 213 
effect of PARP1 in BRAFV600E-expressing cells as shown by similarly increased cell growth in 214 
crystal violet staining (Supplementary Fig. 17a), an increased percentage of BrdU-positive 215 
cells and reduced G0/G1 population in PARP1-expressing cells (Fig. 6b), nor did it affect 216 
H3K9Me3 focus formation (Supplementary Fig. 17b).  We also tested a catalytically inactive 217 
mutant version of PARP137-39 for effect on melanocyte growth and proliferation (Supplementary 218 
Fig. 18a-d), resulting in similar phenotypes to those observed using BYK204165. 219 
 220 
PARP1 transcriptionally activates MITF 221 
To begin to understand the mechanism of PARP1-mediated senescence rescue we first 222 
examined ROS content changes in BRAFV600E and/or PARP1 over-expressing melanocytes. 223 
While we observed a minor increase of ROS content by BRAFV600E expression, we did not 224 
detect meaningful changes in ROS content by PARP1 in our melanocyte system (data not 225 
shown). We then turned our attention to melanocyte lineage survival oncogene, MITF, which is 226 
frequently amplified in malignant melanomas and can transform melanocytes in the context of 227 
BRAFV600E 35. Previous studies have observed that MITF expression is inhibited by oncogenic 228 
BRAFV600E in melanomas40.  Consistent with this finding, we demonstrate that persistent 229 
activation of MAPK pathway by BRAFV600E also suppressed MITF expression in primary 230 
melanocytes (Fig. 6a). Significantly, PARP1 induction, at either strong (Fig. 6a, Supplementary 231 
Fig. 19) or more modest levels (Supplementary Fig. 16e-f), increases MITF at both mRNA and 232 
protein levels, in a PARylation-independent manner (Supplementary Fig. 18d-f, Fig. 6a). 233 
PARP1 also partially restores MITF expression in BRAFV600E-expressing melanocytes, 234 
suggesting a link between OIS rescue and MITF restoration (Fig. 6a, Supplementary Fig. 235 
16e,f, Supplementary Fig. 18d-f, Supplementary Fig. 19). Consistent with this finding, we 236 
observed a weak but significant positive correlation between PARP1 and MITF transcript levels 237 
(Supplementary Fig. 20) LQPHODQRPDVDPSOHVIURP7&*$3HDUVRQ¶Vr = 0.198, P = 5.7 x 238 
10-5) as well as in the smaller subset of 189 tumors that are copy-neutral at the MITF locus 239 
3HDUVRQ¶Vr = 0.252, P = 4.8 x 10-4). To address potential issues with tumor heterogeneity and 240 
random factors driving this correlation in melanomas, we also looked at the correlation in our 241 
early-passage melanoma cell lines. While we did not observe a significant correlation in the full 242 
set of FHOOOLQHV3HDUVRQ¶Vr = 0.15, P = 0.26; Supplementary Fig. 21a), when we further 243 
subdivide them into MITF-high and MITF-low groups to account for distinct cellular states 244 
signified by MITF levels41, a strong correlation of PARP1 and MITF levels was observed only in 245 
MITF-high group 3HDUVRQ¶Vr = 0.560, P = 5.5 x 10-3, n = 23; P = 6.6 x 10-3 when MITF copy 246 
number is adjusted; Supplementary Fig. 21b). A trend of association with PARP1 levels were 247 
also observed in a subset of MITF target genes (Supplementary Fig. 21c-d, Supplementary 248 
Table 12).  249 
MITF is an essential melanocyte survival gene, and therefore we could not directly test if 250 
MITF mediates PARP1 senescence rescue by knocking down MITF in our system. While MITF 251 
depletion by shRNA dramatically reduces melanocyte growth approximately two weeks 252 
following knockdown (Fig. 6c,d), at an earlier time point (D9 after infection), we noticed that 253 
MITF depletion itself introduced a weak but distinct senescence-associated H3K9Me3 254 
phenotype (Fig. 6e) as previously reported 42. Interestingly, in the context of MITF knockdown, 255 
PARP1 senescence rescue is not observed in terms of partial reversal of H3K9Me3 focus 256 
formation (Fig. 6e). These results suggest that PARP1 function in senescence rescue is likely 257 
upstream of MITF expression.  258 
Given that PARP1 activates MITF at the mRNA level, we performed ChIP to determine 259 
whether PARP1 directly localizes to the melanocyte-specific MITF-M 43,44 promoter in human 260 
primary melanocytes. ChIP experiments were performed both via overexpression of PARP1 in 261 
melanocytes, as well as in melanocytes expressing endogenous levels.  Among seven primer 262 
sets spanning the MITF-M promoter region (±1263 to +172bp of the transcription start site; 263 
TSS), the two that are more proximal to the TSS displayed the most significant enrichment, 264 
indicating PARP1 binding (~8-19 fold above IgG background at endogenous level, Primer4 and 265 
Primer5, from -587 to -136 bp; Fig. 7). Localization of PARP1 to the MITF-M promoter was 266 
observed both with PARP1 over-expression as well as endogenous levels, while no detectable 267 
enrichment was observed when PARP1 was knocked down using an shRNA (data not shown). 268 
Notably, the region where PARP1 localizes overlaps with consensus binding sites of previously 269 
known transcriptional regulators of the MITF-M promoter: SOX10, TCF/LEF, and CRE (Fig. 7); 270 
and a putative PARP1 binding motif45 was also predicted in this core region (see Methods 271 
section). 272 
To assess whether PARP1 directly regulates MITF transcription, we performed 273 
luciferase reporter assays using constructs containing the MITF-M promoter regions46. Altered 274 
PARP1 levels via over-expression or shRNA-mediated knockdown failed to modulate reporter 275 
activity (Supplementary Fig. 22), suggesting a potential epigenetic role for PARP1 in regulation 276 
of the MITF-M locus that is not recapitulated via ectopic expression of a reporter gene. Bisulfite 277 
sequencing of two assayable CpGs near the MITF-M TSS47 indicated that introduction of 278 
BRAFV600E does not alter their methylation status (Supplementary Fig. 23), speaking against 279 
DNA methylation-mediated regulation in this context. Examination of a promoter histone mark, 280 
H3K4Me3, by ChIP revealed that H3K4Me3 is enriched in the MITF-M proximal promoter when 281 
PARP1 is expressed either endogenously or ectopically (Supplementary Fig. 24a), but is 282 
diminished upon knocking down PARP1 expression (Supplementary Fig. 24b). Furthermore, 283 
expression of BRAFV600E resulted in diminished H3K4Me3 signal in the MITF-M promoter, but 284 
was restored to the usual high levels upon co-expression with PARP1 (Supplementary Fig. 285 
24c). ChIP analyses using antibodies recognizing the C-terminal domain (CTD) of RNA 286 
polymerase II (RNA Pol II) or CTD with phosphorylated Serine 5 demonstrated that RNA Pol II 287 
and its initiation-signature, Serine 5 phosphorylation, are both enriched near M-MITF TSS at 288 
endogenous PARP1 levels, but diminished upon PARP1 knock-down (Supplementary Fig. 25). 289 
These results are consistent with a model in which PARP1 influences MITF-M promoter activity 290 
and influences MITF levels via transcriptional regulation.  291 
 292 
  DISCUSSION 293 
In this study, eQTL and ASE analyses suggest PARP1 as the susceptibility gene 294 
underlying the melanoma risk locus on chromosome band 1q42.1. When we evaluated the set 295 
of genes in +/- 1Mb of the lead melanoma risk SNP (rs3219090) to account for potential long-296 
range regulation, we observed a highly-reproducible eQTL with PARP1, but not with other 297 
nearby genes. The correlation between the risk allele and higher levels of PARP1 expression 298 
was highly reproducible across multiple melanoma-relevant tissues, including early-passage 299 
melanoma cell lines, melanoma tumors, and human skin biopsies in both eQTL and ASE 300 
analyses.  While eQTL and ASE analyses cannot completely rule out a potential role for other 301 
genes within the larger genomic region surrounding the GWAS peak, these data strongly 302 
implicate PARP1 as functionally mediating melanoma risk at this locus.  303 
While this region is relatively small in size, 65 variants are nonetheless strongly 304 
correlated (r2>0.6) with the lead GWAS SNP.  To efficiently prioritize functional candidates we 305 
took advantage of potential gene regulatory regions annotated in human melanocyte and 306 
melanoma samples by the ENCODE and Roadmap Projects.  We chose to focus on variants 307 
located in most consistently annotated regulatory elements across different individuals and 308 
cellular conditions because of the strikingly consistent eQTL and ASE data observed in both 309 
melanocytes and melanomas. Subsequent characterization of these candidate variants 310 
highlighted a single variant, rs144361550, as a strong functional candidate. Of the variants 311 
tested, only rs144361550 demonstrated both allele-specific transcriptional activity and protein 312 
binding pattern in a manner consistent with the observed pattern of genotype/expression 313 
correlation. While these data provide support for rs144361550 as a functional melanoma risk 314 
variant influencing levels of PARP1 expression, they nonetheless cannot rule out other variants 315 
in this region as also contributing to the observed correlation between PARP1 levels and 316 
genotype.   317 
Our unbiased approach using quantitative mass-spectrometry identified RECQL as a 318 
protein binding allele-preferentially to rs144361550. Importantly, RECQL binding to 319 
rs144361550 does not appear to be driven by sequence specificity but rather by DNA 320 
secondary structure. While genomic sequence encompassing rs144361550 suggested G4-321 
forming potential (Supplementary Table 11), which might explain a regulatory role48, our in 322 
vitro assays failed to provide definitive evidence for G4 structure either by insertion or deletion 323 
allele. However, formation of another differential structural motif, such as a transient hairpin 324 
structure (formed by single-stranded sequences, Supplementary Table 13) or a locally 325 
perturbed double-helix structure at the hexanucleotide repeat domain49, inducing DNA bending 326 
and serving as a recognition motif for allele-specific protein binding50, cannot be excluded.   327 
Although PARP1 is most well-known for its role in DNA repair, to date GWAS have 328 
identified this region only for melanoma susceptibility (GWAS catalog; see URL section), 329 
suggesting a potential melanoma-specific role of PARP1. Indeed, ectopic expression of PARP1 330 
led to increased melanocyte proliferation both alone, as well as in the presence of oncogenic 331 
mutated version of BRAF (BRAFV600E). BRAFV600E is found in most melanocytic nevi51, and as 332 
reported earlier31 its over-expression in primary melanocytes led to markedly decreased cell 333 
proliferation as well as H3K9Me3 focus formation, a hallmark of cellular senescence52.  Our data 334 
show that these senescence-like phenotypes are partially reversed by elevated PARP1 levels. 335 
Further, ectopic expression of PARP1 in TERT-LPPRUWDOL]HGS¶PHOPHODQRF\WHVH[SUHVVLQJ336 
BRAFV600E 35 led to a tumorigenic phenotype exemplified by anchorage-independent growth. 337 
These data suggest a role for increased PARP1 in the early stages of melanomagenesis 338 
promoting increased melanocyte growth and/or escape from BRAFV600E-induced senescence. In 339 
this context, PARP1 seems to be functionally linked to melanocyte lineage survival oncogene, 340 
MITF, which itself is an established melanoma susceptibility gene53,54. While we did not 341 
exhaustively explore all the major functions of PARP1 including DNA repair and inflammation in 342 
the context of melanomagenesis, our findings highlight a novel role for PARP1 in a melanocyte-343 
specific context, providing a potential link between a susceptibility gene and a lineage-specific 344 
oncogene.  345 
Most well-established functions of PARP1 are dependent on the poly-ADP ribosylation 346 
activity including its role in DNA damage response and repair.  While some transcriptional co-347 
regulator functions of PARP1 do not require its enzymatic activity24,25, the role of PARP1 in 348 
chromatin structure modification mainly relies on NAD+-dependent association with 349 
nucleosomes55 or PARylation of histones and chromatin modulators such as histone 350 
demethylase KDM5B56,57.  Notably, the effects of PARP1 expression on melanocyte 351 
proliferation, BRAFV600E-induced senescence, and restoring MITF-M expression do not appear 352 
to depend on the catalytic activity of PARP1. Interestingly, PARP1-mediated MITF-M up-353 
regulation seems to involve chromatin modulation, as the promoter histone mark H3K4Me3 is 354 
markedly enriched near the TSS of MITF-M upon PARP1 expression relative to its depleted 355 
state in BRAFV600E-expressing melanocytes. While this is an important observation of potential 356 
PARylation-independent chromatin modulation function, further investigation is required to 357 
establish a causal relationship and molecular link.  358 
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 537 
Figure 1  The melanoma risk-associated G allele of rs3219090 is correlated with increased PARP1 538 
expression.  (a) eQTL analysis was performed for rs3219090 using expression microarray and SNP array 539 
genotypes derived from a panel of 59 early-passage melanoma cell lines.  A significant eQTL was 540 
observed for PARP1, and the result is plotted for rs3219090 genotype (P = 1.4 x 10-3; linear regression). 541 
G is the risk allele and A the protective allele of rs3219090. A.U.; arbitrary unit.  (b) The allelic ratios of 542 
PARP1 transcripts were measured in 14 copy-neutral melanoma cell lines that were heterozygous for 543 
both rs3219090 and a synonymous mRNA-coding surrogate SNP (rs1805414, r2=0.98 with rs3219090) 544 
using Taqman genotyping assays.  Allelic ratios were inferred from a known amount of allelic standards 545 
and plotted as a ratio of PARP1 expression from the risk over protective allele (P = 1.2 x 10-4, two-tailed 546 
Wilcoxon signed rank test, average value of PCR triplicates were considered as a single data point).  (c) 547 
Allelic ratios of PARP1 transcripts were measured using RNA sequencing data from 48 copy-neutral 548 
TCGA skin melanoma samples that were heterozygous for both rs3219090 and rs1805414.  The mapped 549 
numbers of RNAseq reads encompassing each allele of rs1805414 were used for calculating allelic ratios 550 
(P = 0.011, two-tailed Wilcoxon signed rank test).  Solid line marks 1:1 ratio, and dashed line represents 551 
median ratio.  552 
 553 
Figure 2  Functional annotation of a 3kb region encompassing rs144361550 in primary melanocytes. 554 
Histone modifications (H3K4Me1, H3K4Me3, and H3K27Ac) and DNaseI hypersensitivity sites (DHS) in 555 
primary melanocytes are shown for a 3kb region encompassing rs144361550. The red dashed vertical 556 
line indicates the position of rs144361550, overlapping histone marks, DHS, and transcription factor 557 
binding sites. Genomic positions are based on hg19. Transcription factor binding sites are from UCSC 558 
JHQRPHEURZVHUWUDFN³7UDQVFULSWLRQ)DFWRU&K,3-seq (161 factors) from ENCODE with Factorbook 559 
0RWLIV´UHSUHVHQWLQJPXOWLSOH(1&2'(FHOOW\SHV³&KURPDWLQ3ULPDU\&RUH0DUNV6HJPHQWation by HMM 560 
IURP5RDGPDS3URMHFW´WUDFNLVDOVRVKRZQIRUWKUHHPHODQRF\WHVDPSOHV7VV$$FWLYHB7667VV)561 
Flanking_Active_TSS, Enh: Enhancers. For DHS, traces from two experimental replicates of Melanocyte 562 
1 and 2 are displayed. The scale of each track is uniformly set throughout the region of the PARP1 gene 563 
to cover the highest peaks, with 0 as the baseline (see online methods for details of each track). 564 
 565 
Figure 3  The melanoma-associated indel, rs144361550, drives allelic transcriptional activity and protein 566 
binding. (a,c) Luciferase assays for rs144361550 were conducted using the melanoma cell line 567 
UACC2331 (a) or primary melanocytes (c). 905bp or 22/28bp encompassing rs144361550, respectively, 568 
ZHUHFORQHG¶RIPLQLPDOSURPRWHULQS*/YHFWRUDQGtransfected into the cells. Luciferase activity 569 
was measured 24hrs after transfection and was normalized against Renilla luciferase activity. Relative 570 
luciferase levels were plotted as percent of the minimal promoter control. P-values are shown or * P < 571 
0.05 against Ctrl (two-tailed, paired t-test). Two (a) and three (c) independent cell cultures and 572 
transfections of n = 3 were combined to present the median with range, 75 & 25 percentiles, and each 573 
data point. Ctrl: minimal promoter control, Del: deletion/risk allele construct, Ins: insertion/protective allele 574 
construct.  (b,d) EMSA was performed using biotin-labeled double stranded oligos for the deletion/risk 575 
(Del, D) or insertion/protective (Ins, I) alleles of rs144361550 and nuclear extracts from melanoma cell 576 
lines UACC2331 and UACC457 (b) or primary melanocytes (d). Sequences shown in panel b for the 22 577 
bp deletion and 28 bp insertion probes were used for both b and d (bold and Italic bases highlight 578 
potential G4 structure forming nucleotides). 50X, 200X or 500X molar excess of unlabeled competitors 579 
were added in specified lanes.  580 
Figure 4  RECQL binds to the insertion allele and mediates allelic expression.  (a) Insertion allele-specific 581 
binding proteins were identified by mass-spectrometry using melanoma cell nuclear extract and 582 
biotinylated double-stranded oligos. The ratio of proteins bound to heavy/light-dimethyl labeled probes is 583 
plotted on x and y-axis for labeling swapping.  Red circles: enriched above the background in both 584 
directions. Circle sizes represent relative abundance. (b) RECQL EMSA/supershift. D: deletion, I: 585 
insertion (c) ChIP was performed using anti-RECQL antibody or IgG and melanoma cell chromatin 586 
followed by qPCR. DNA quantity was normalized to input DNA for each IP (n=3). Neg: gene desert, Pos: 587 
a known RECQL binding locus, Indel: rs144361550 region. A representative set from four independent 588 
experiments is shown. (d) RECQL under tetracycline-inducible promoter was expressed in three 589 
melanoma cell lines. PARP1 levels (top) and RECQL RNA (middle) and protein (bottom) levels were 590 
measured at 48hrs of doxycycline induction (blot images were cropped). Transcript levels are shown as 591 
fold over Empty vector after normalizing to B2M control (n = 6, 5, and 6 for each cell line). (e) Luciferase 592 
assays were performed using 905bp deletion (Del) or insertion allele (Ins) constructs with RECQL or 593 
Empty vector co-transfection in HEK293FT cells. Renilla-normalized relative luciferase activities were 594 
plotted as percent of the minimal promoter control (Ctrl) (n = 6). (c-e) Each graph shows median with 595 
range, 75 & 25 percentiles, and each data point. Two-tailed, t-test assuming unequal variance for all P-596 
values shown. * P < 0.05 against Ctrl (e) or Empty (d). 597 
 598 
Figure 5  Cell growth and H3K9Me3 focus formation in primary human melanocytes expressing PARP1 599 
and BRAFV600E.  (a) Crystal violet (CV) staining of melanocytes expressing PARP1, BRAFV600E, or both.  600 
Cells were first infected with pIN20-PARP1 followed by G418 treatment and doxycycline induction. Cells 601 
were then infected with HIV-CSCG-BRAFV600E vector at day 6 after PARP1 infection followed by 602 
blasticidine selection.  Equal cell numbers were seeded at day 11 after pIN20-PARP1 infection and 603 
stained with CV 9 days after seeding.  (b)  BrdU staining of primary human melanocytes expressing either 604 
PARP1, BRAFV600E, or both.  BrdU staining was done at day 13 after initial infection of pIn20-PARP1 (n = 605 
4, median with range and 25 & 75 percentiles, t-test assuming unequal variance, representative set from 606 
three experiments). (c) H3K9Me3 staining of primary human melanocytes at day 13 after initial infection. 607 
Scale bars are shown for 10µm. (d) Colony formation in soft-DJDURIS¶PHOBRAFV600E cells expressing 608 
either PARP1 or MITF-M.  Immortalized melanocytes (S¶PHOFHOOV) expressing active BRAFV600E were 609 
infected with pLX304 empty, pLX304-PARP1 or pLX304-MITF and seeded in soft-agar plates after 610 
blasticidine selection.  Images were taken at day 22 and colonies were counted from two sets of 611 
triplicates at day 26 after plating (n=6, from two experiments, median with range and 25 & 75 percentiles). 612 
t-test assuming unequal variance (e) Representative images of colonies are shown. The same 613 
magnification (40X) was applied for all the images. 614 
 615 
Figure 6  MITF expression is restored in primary human melanocytes co-expressing PARP1 and 616 
BRAFV600E in a PARylation-independent manner, concurrent with partial reversal of senescence 617 
phenotypes. (a) Western blot detection of MITF (long and short exposures), BRAF, PARP1, and PAR. 618 
Primary human melanocytes were co-infected with PARP1, BRAFV600E followed by treatment with the 619 
PARP inhibitor, BYK204165. Cell extract was generated at day 13 after initial infection with PARP1 620 
construct. Blot images were cropped. (b) BrdU flow cytometry of primary human melanocytes co-infected 621 
with PARP1, BRAFV600E, and/or MITF-shRNA followed by treatment with the PARP inhibitor, BYK204165. 622 
(c) Crystal Violet staining of melanocytes co-infected with PARP1, BRAFV600E, and/or MITF-shRNA.  623 
Primary melanocytes were first infected with pIN20-PARP1 or empty pIN20 vector concurrently with 624 
pLKO-shRNA-MITF-M or pLKO-empty vector followed by G418 treatment and doxycycline induction. 625 
Cells were then infected with HIV-CSCG-BRAFV600E or empty HIV-CSCG vector at day 6 after PARP1 626 
infection followed by Blasticidine selection. A representative crystal violet (CV) staining (n=3) image is 627 
displayed at day 17 of infection. (d) Quantification of solubilized CV staining by measuring absorbance at 628 
540nm at day 17 of infection is plotted. Median with range (n=3, t-test assuming unequal variance, a 629 
representative set from three experiments is shown) (e) PARP1-mediated partial reversal of BRAFV600E-630 
induced H3K9Me3 focus formation in melanocytes is blocked by knockdown of MITF. H3K9Me3 staining 631 
was performed at day 13 after initial infection. Scale bars are shown for 10µm. 632 
 633 
Figure 7  PARP1 binds to MITF-M promoter. Human melanocytes were transduced with lentiviral 634 
constructs of empty pIN20 (Empty = endogenous PARP1 levels) or PARP1 cDNA (PARP1 = over-635 
expression of PARP1) and harvested five days after infection. Chromatin immunoprecipitation was 636 
performed using antibody against PARP1 (anti-PARP1) or rabbit normal IgG (IgG) and pulled-down DNA 637 
was amplified using seven sets of primers spanning -1263bp through to +172bp relative to MITF-M TSS 638 
(black arrow). Gray arrows depict locations of qPCR primers relative to the genomic region of MITF-M 639 
promoter shown below. Relative quantities were calculated by normalizing each sample amount to 640 
matched input DNA. Average quantity with range, and individual data points for qPCR triplicates are 641 
shown. Experiments were repeated 3 times yielding similar results, and the results from a representative 642 
set are displayed. Known (closed symbols) or predicted (open symbols) binding sites for transcription 643 
factors are presented to their relative genomic positions on MITF-M promoter. The genomic sequence of -644 
325bp through to -150bp relative to the TSS are shown in the box, with known or predicted transcription 645 
factor binding sites underlined.  646 
ONLINE METHODS 647 
Early passage melanoma cell line eQTL analysis.  Early passage melanoma cell lines were 648 
obtained from the University of Arizona Cancer Center (UACC), and eQTL analysis was 649 
performed by combining gene expression profiling and SNP genotyping data. The use of cell 650 
lines was approved by National Institutes of Health Office of Human Subject Research. Early 651 
passage melanoma cell lines were grown in the medium containing RPMI1640, 10% FBS, 20 652 
mM HEPES, and penicillin/streptomycin until ~70% confluent. All cell lines were tested negative 653 
for mycoplasma contamination. For RNA isolation, cells were washed twice with cold PBS on 654 
ice and lysed with Trizol.  Trizol was heated to 65ºC for 5 min to maximize melanin removal.  655 
Following heating, 1 mL chloroform was added per 5 mL of Trizol, vortexed, cooled on ice for 5 656 
min, and centrifuged.  The aqueous phase was removed, and equal volume of 70% EtOH was 657 
added dropwise while vortexing at low speed.  Ethanol /supernatant mixtures were added to 658 
Qiagen RNeasy midi columns, with the flow-through reapplied once.  Samples were then 659 
SURFHVVHGSHUPDQXIDFWXUHU¶VSURWRFRO51$TXDQWLW\DQGLQWHJULW\ZHUHDVVHVVHGXVLQJ660 
Bioanalyzer, which yielded RIN>7 for all samples.  Total RNA were expression profiled on 661 
Affymetrix U133Plus2 expression microarrays, with labeling, hybridization, washing, and 662 
VFDQQLQJSHUIRUPHGDFFRUGLQJWRPDQXIDFWXUHU¶VSURWRFRO%DFNJURXQGFRUUHFWLRQDQGTXDQWLOH663 
normalization of gene expression data were performed using Robust Multi-array Average (RMA) 664 
algorithm with the default settings (Affymetrix). For genomic DNA isolation, Qiagen DNeasy 665 
Blood and Tissue kit was used.   DNA quantity was measured using NanoDrop and PicoGreen 666 
fluorescent assay. All samples were profiled using Applied Biosystems Identifiler STR panel 667 
prior to genotyping on Illumina OmniExpress arrays. After quality assessment of genotypes 668 
samples with >0.1 missing rate were excluded from the analysis. Loci with > 0.1 missing rate, 669 
MAF < 0.01, or Hardy-Weinberg Equilbrium P- value < 5E-5 were also excluded. The genomic 670 
region encompassing 6Mb around the GWAS lead SNP rs3219090 (which was directly 671 
genotyped on the array) was imputed using IMPUTE2.2.258 and 1KG phase1 v3 April 2012 672 
(build 37) as a reference data. After assigning imputed genotypes for 2 samples that were 673 
missing direct genotype for rs3219090 (recoded as 0.333 probability of each genotype), 59 total 674 
samples were qualified for eQTL analysis with gene expression and genotype data available. 675 
Affymetrix U133Plus2 annotates 17 genes and 11 other transcripts in the 2 Mb region centering 676 
at rs3219090. Among these, probes for 12 genes and 2 other transcripts passed QC, including 677 
PARP1. eQTL analysis was then performed for these samples and gene/transcripts using 678 
SNPTEST v2.5 (see URL section) considering an additive model for genotypes. 679 
Allele discrimination qPCR.  cDNA from early passage melanoma cell lines heterozygous for 680 
both rs3219090 and coding surrogate SNP rs1805414 as well as of normal genomic copy were 681 
assayed using custom-designed Taqman genotyping probe sets that do not recognize genomic 682 
DNA.  To act as a standard, the same amplicon was PCR-amplified for each allele from cDNA 683 
and subsequently cloned into the pCR2.1 TOPO vector (Invitrogen) and sequence verified. A 684 
standard curve was then generated using known amounts of cloned amplicons by plotting 11 685 
different points of allelic ratio against VIC/FAM signal ratio.  Allele discrimination qPCR was 686 
performed in triplicate, and allelic ratio was calculated from the average ratio of VIC/FAM signal 687 
using the standard curve. Departure from expected allelic ratio (major/minor allele) of 1 was 688 
assessed using two-tailed Wilcoxon signed rank test. 689 
Nomination of candidate functional variants.  All LD r2 values used for candidate variant 690 
nomination were from 1KG phase 3 data. r2 values based on both the EUR and CEU 691 
populations were considered to extract the maximum r2 of each variant with the lead SNPs, 692 
rs3219090 and rs1858550. Meta-analysis P-values were obtained from the previously published 693 
work of Law and colleagues7; all samples used in the meta-analysis were collected with 694 
informed consent and ethics committee approvals as previously described.  DHS peaks for the 695 
SULPDU\KXPDQPHODQRF\WHFXOWXUH³PHODQR´(1&2'('XNHZHUHREWDLQHGIURP(1&2'(696 
database26 through UCSC Genome browser (see URL section).  DNase-seq data for penis 697 
IRUHVNLQPHODQRF\WHSULPDU\FHOOFXOWXUHV³VNLQ´DQG³VNLQ´(shown as Melanocyte_1 and 698 
Melanocyte_2 in Fig 2 and Supplementary Fig 2) were obtained from Roadmap database 699 
(03/09/2015) and DHS peaks were called using MACS59(see URL section) using the default 700 
settings and FDR 1% cutoff.  DHS peak intervals were overlaid with the genomic position of 701 
each candidate variant to determine whether each candidate localizes within a DHS peak.  702 
Experimental duplicates for skin 01 (DS18590, DS18601) and skin 02 (DS19662, DS18668), 703 
and analytical duplicates for melano were used for our analysis.  To call a variant to be within 704 
DHS in one sample, DHS overlapping the variant in either of the duplicates were counted.  DHS 705 
peaks from DNase-seq data for two melanoma cell lines Mel2183 (ENCODE/Duke) and RPMI-706 
7951 (ENCODE/UW) were obtained from the ENCODE database.  Peaks from FAIREseq data 707 
for 11 melanoma culture samples were obtained from GEO (accession number: GSE60666). 708 
Histone mark annotation was performed in the same way. Primary melanocyte histone marks 709 
were taken from subsets of three individuals through Roadmap database (skin 01, skin 02, and 710 
skin 03; shown as Melanocyte_1, Melanocyte_2, and Melanocyte_3 in Fig 2 and 711 
Supplementary Fig 2). Source of each track visualized on UCSC genome browser is as 712 
follows: Melanocyte track names used for Fig 2 (Track 1: UCSF-UBC-USC Penis Foreskin 713 
Melanocyte primary Cells Histone H3K27ac Donor skin03 Library A15584 EA Release 9, Track 714 
2: UCSF-UBC-USC Penis Foreskin Melanocyte primary Cells Histone H3K4me1 Donor skin03 715 
Library A15579 EA Release 8, Track 3: UCSF-UBC-USC Penis Foreskin Melanocyte primary 716 
Cells Histone H3K4me3 Donor skin03 Library A15580 EA Release 8, Track 4: Melano DNaseI 717 
HS Density Signal from ENCODE/Duke, Track 5: Penis Foreskin Melanocyte Primary Cells 718 
Donor skin 01 DNase Uniformly Signal from Roadmap, Track 6: UW Penis Foreskin Melanocyte 719 
Primary Cells DNase Hypersensitivity Donor skin02 Library DNase DS19662 EA Release 9.), 720 
Melanoma track names used for Supplementary Fig 2 (Track 1 through 11: H3K27ac ChIP-seq 721 
signal from F-seq, Track 12 through 22: FAIRE-seq signal from F-seq, Track 23: Mel2183 722 
DNaseI HS Density Signal from ENCODE/Duke, Track 24: RPMI-7951 DNaseI HS Raw Signal 723 
Rep 1 from ENCODE/UW.). 724 
Luciferase reporter assays.  Luciferase constructs were generated to include the DHS region 725 
encompassing each SNP.  Sequences encompassing each variant were amplified from 726 
genomic DNA of HapMap CEU panel samples using the primers listed in Supplementary Table 727 
14, cloned into pCR2.1TOPO vector, and subsequently cloned into pGL4.23 vector using 728 
EcoRV and HindIII enzymes or directly into pGL4.23 vector using primers with HindIII and XhoI 729 
sequence overhangs.  Sequence-verified pGL4.23 constructs were then co-transfected with 730 
pGL4.74 (Renilla luciferase) into a melanoma cell lines UACC2331, UACC457, or UACC1308  731 
using Lipofectamine 2000 reagent (Thermo Fisher) or electroporation with Lonza Amaxa SE kit 732 
and DS-150 protocol on 4D-Nucleofector system. Electoporation of primary human melanocytes 733 
(HEMn-LP, Invitrogen) was performed using the Lonza Amaxa P2 kit and protocol CA-137 734 
(Lonza).  When luciferase assays were combined with RECQL over-expression, empty pCMV6-735 
Entry vector or human RECQL cDNA clone (Origene, RC200427) were co-transfected with 736 
luciferase constructs into HEK293FT cells using Lipofectamine 2000 reagent.  Cells were 737 
collected 24hr following transfection and luciferase activity was measured using Dual-Luciferase 738 
reporter system (Promega) on GLOMAX multi detection system (Promega). All cell lines and 739 
primary cultures used here and onward were tested negative for mycoplasma contamination. 740 
EMSA and antibody supershift.  Nuclear extracts were prepared from actively growing normal 741 
human melanocytes (HEMn-LP, Invitrogen or melanoma cell lines (UACC) using NE-PER 742 
nuclear and cytoplasmic extraction kit (Thermo Scientific). DNA oligos for each variant were 743 
V\QWKHVL]HGZLWK¶ELRWLQODEHOLQJDQG+3/&-purified (Life Technologies; probe sequences are 744 
listed in Supplementary Table 14).  Forward and reverse strands were then annealed to make 745 
double stranded DNA probes. Probes were bound to 0.5-4µg nuclear extracts pre-incubated 746 
with 1µg poly d(I-C) in binding buffer containing 10mM Tris (pH 7.5), 50 mM KCl, 1 mM DTT, 10 747 
mM MgCl2, with or without 5% glycerol at 4ºC for 30min.  Unlabeled competitor oligos were 748 
added to the reaction mixture 5min prior to the addition of probes.  Completed reactions were 749 
run on 5% or 4-20% native acrylamide gel and transferred blots were developed using LightShift 750 
Chemiluminescent EMSA kit (Thermo Scientific) and exposed on film.  Supershift antibodies 751 
(RecQL, sc-25547, Santa Cruz) or rabbit normal IgG (sc-2027, Santa Cruz) were bound to 752 
nuclear extract prior to poly d(I-C) incubation at 4 ºC for 1hr. EMSAs with purified recombinant 753 
protein were performed using RECQL (TP300427, Origene), where purified recombinant 754 
proteins were used in place of nuclear extract and poly d(I-C). Additional antibodies and 755 
recombinant proteins for validations are as follows. Antibodies are from Santa Cruz unless 756 
otherwise specified: anti-NCL (sc-8031), anti-SRSF3 (sc-13510), anti-CIRP (sc-161012), anti-757 
BLM (sc-7790), anti-hnRNPD (sc-22368), anti-RBM3 (sc-162080), anti-TOP3A (sc-11257), anti-758 
RPA1 (sc-14696), anti-DHX36 (A300-525A, Bethyl), anti-RPA3 (ab167593, Abcam). 759 
Recombinant proteins are from Origene: NCL (TP319082), CIRP (TP301639), 760 
RPA1(TP302066), hnRNPD (TP300660), RBM3 (TP760298). 761 
Mass-spectrometry.  Quantitative AP-MS/MS following SNP DNA pulldown and in-solution 762 
dimethyl chemical labeling was performed based on procedures described previously29,30.  763 
Nuclear extract from the melanoma cell line UACC2331 was collected as described previously 764 
using the Dignam lysis protocol60. For DNA pulldowns, 500 pmol RIDQQHDOHGIRUZDUGVWUDQG¶-765 
biotinylated oligo probes were coupled to streptavidin sepharose beads (GE Healthcare). 766 
Insertion and deletion allele probe sequences are listed in Supplementary Table 14. Beads 767 
were incubated with 450 µg of nuclear extract for 90 minutes plus 10 µg of non-specific 768 
competitor DNA (either 10 µg of poly-dAdT or 5 µg of poly-dAdT plus 5 µg poly-dIdC). After 769 
washes, beads were resuspended in 100mM TEAB buffer, proteins were reduced with 5mM 770 
TCEP, alkylated with 10 mM MMTS, and digested overnight with 0.25 µg trypsin. Digested 771 
peptides were labelled using in-solution dimethyl chemical labelling as described previously28. 772 
All experiments were performed in duplicate, and labels were swapped between replicate pairs 773 
to prevent labeling bias. Heavy and light labelled peptides were mixed and prepared using C18-774 
StageTips. Peptides were loaded on a column packed with 1.8 µm Reprosil-Pur C18-AQ beads 775 
(gift from Dr. Maisch) and eluted using a 120 minute gradient from 7%-32% buffer B (80% 776 
acetonitrile, 0.1% formic acid) at a flow rate of 250nL/min. Peptides were sprayed directly onto a 777 
Thermo QExactive mass spectrometer. Data was collected in top10 data-dependent acquisition 778 
mode. Thermo RAW files were analyzed with MaxQuant (version 1.3.0.5) by searching against 779 
the Uniprot curated human proteome. Methionine oxidation and N-terminal acetylation were 780 
considered as variable modifications and cysteine-dithiomethane was set as a fixed 781 
modification. Protein ratios normalized by median ratio shifting as described previously61 were 782 
used for outlier calling. An outlier cutoff of 1.5 IQRs (inter-quartile ranges) in two out of two 783 
biological replicates was used.  784 
Chromatin immunoprecipitation of RECQL.  UACC2331 melanoma cells or primary human 785 
melanocytes (HEMn-LP, Invitrogen) were fixed with 1% formaldehyde when 80-90% confluent, 786 
following the instructions of Active Motif ChIP-ITexpress kit or ChIP-IT high sensitivity kit.  7.5 x 787 
106 cells were then sheared by sonication using a Bioruptor (Diagenode) at high setting for 788 
15min, with 30 sec on and 30 sec off cycles. Sheared chromatin from 1 to 4 x 106 cells were 789 
used for each immunoprecipitation with antibodies against RECQL, H110 (sd-25547; Santa 790 
Cruz), and A300 (A300-450A; Bethyl), or normal rabbit IgGs (sc-2027; Santa Cruz) following the 791 
PDQXIDFWXUHU¶VLQVWUXFWLRQV3XULILHGSXOOHG-down DNA was assayed by SYBR Green qPCR for 792 
enrichment of target sites using primers listed in Supplementary Table 14. A commercial 793 
primer set (71001, Active Motif) recognizing a gene desert on chromosome 12 was used for a 794 
negative control (Neg).  795 
Overexpression of RECQL in melanoma cell lines.  RECQL was cloned from a cDNA 796 
construct (RC200427, purchased from Origene) into lentiviral pLU-TCMV-FMCS-pPURO vector 797 
DJHQHURXVJLIWIURP'U0HHQKDUG¶VODEDW:LVWDUcontaining tetracycline-inducible promoter. 798 
Lentiviral vectors were co-transfected into 293 cells with packaging vectors psPAX2, pMD2-G, 799 
and pCAG4-RTR2.  Virus was collected two days after transfection and concentrated by 800 
Vivaspin.  Cells were incubated with virus for 24 hr, followed by puromycin (1-2 µg/ml) selection 801 
for 2-3 days. After drug selection cells were seeded and grown in the media containing varying 802 
amount of doxycycline (0,0.5, and 1 µg/ml). Cells were harvested after 48 hrs of doxycycline 803 
induction for RNA and protein isolation. cDNA was generated from total RNA and transcript 804 
levels were measured using Taqman qPCR. RECQL and PARP1 transcript levels normalized to 805 
the levels of B2M, and PCR triplicates were averaged and considered as one data point. 806 
Western blotting of RECQL and GAPDH was performed using the following antibodies: 807 
RecQL1, sc-25547, Santa Cruz, GAPDH, sc-51907, Santa Cruz.  808 
Lentiviral vectors and lentiviral infection of melanocytes.  HIV-CSCG-BRAFV600E was used 809 
to express BRAFV600E in normal human melanocytes (provided by Dr. Daniel Peeper, 810 
Netherlands Cancer Institute).  The PARP1 cDNA clone (BC037545) was purchased from 811 
Thermo Scientific and sub-cloned and expressed in three different lentiviral vectors: a. under a 812 
tetracycline-inducible promoter in the pInducer 20 vector backbone (Addgene) as pIN20-813 
PARP1, which expresses high level of PARP1; b. under a tetracycline-inducible promoter in the 814 
pLU-TCMV-FMCS-S3852YHFWRUDJHQHURXVJLIWIURP'U0HHQKDUG+HUO\Q¶VODERUDWRU\DWWKH815 
Wistar Institute) as pLU-TCMV-PARP1 which expresses low level of PARP1; c. with a CMV 816 
promoter in the pLX304 backbone (Addgene) as pLX-PARP1. The PARP1 catalytic mutant 817 
p.Glu988Lys39 was generated using the QuickChange II XL Site-Directed Mutagenesis kit 818 
(Agilent). The MITF-M cDNA clone (NM_000248) was purchased from Origene and was sub-819 
cloned and expressed in pLX304 backone as pLX-MITF. pLKO_MITF shRNAs (a pool of 4 820 
shRNAs with clone IDs from TRC0000019119 to TRC0000019123) were purchased from Sigma 821 
in lenitiviral-based vectors.  Primary human melanocytes were obtained from Invitrogen and/or 822 
the Yale SPORE in Skin Cancer Specimen Resource Core and grown under standard culture 823 
conditions using Medium M254 with supplements (Invitrogen). For lentivirus production, 824 
lentiviral vectors were co-transfected into 293 cells with packaging vectors psPAX2, pMD2-G, 825 
and pCAG4-RTR2.  Virus was collected two days after transfection and concentrated by 826 
Vivaspin.  Cells were incubated with virus for 24 hr, followed by drug selection, before being 827 
subjected to various experimental treatments and assays. Dose of BYK204165 was chosen by 828 
performing a titration assay. Briefly, melanocytes were treated with 1, 5, 20, and 40 µM 829 
BYK204165 for 1, 7, and 24 hrs, and PARylation was assessed by western blotting. PARylation 830 
was mostly diminished with 5 µM BYK204165, and completely undetectable with 20 µM after 1 831 
hour treatment. Based on these data, we chose to use 10 µM BYK204165 for our assays. 832 
Cell proliferation assays.  Cell proliferation was assayed by a bromodeoxyurifine (BrdU) flow 833 
NLW%'3KDUPLQJHQ6DQ-RVH&$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO%ULHIO\FHOOVZHUH834 
labeled with 10µM BrdU for three hours before they were fixed, permeabalized and subjected to 835 
DNaseI treatment.  Cells were then stained with FITC-conjugated anti-BrdU antibody and 7-836 
AAD, followed by flow cytometry analysis using a FACSCalibur (BD Pharmingen, San Jose, 837 
CA).  For most cases, BrdU assay was performed on cells two weeks after initial infection of 838 
PARP1 vector.  For crystal violet (CV) staining, cells were seeded at equal numbers after 839 
infection and drug selection, and stained with CV between 2-3 weeks after initial PARP1 840 
infection.  841 
Western and immunofluorescence staining.  For western blot analysis, total cell lysates were 842 
generated with RIPA buffer (Thermo Scientific, Pittsburgh, PA) and subjected to water bath 843 
sonication.  Samples were resolved by 4-12% Bis-Tris ready gel (Invitrogen, Carlsbad, CA) 844 
electrophoresis.  The primary antibodies used were rabbit anti-PAR (551813, BD Pharmingen, 845 
CA), rabbit anti-PARP (9542, Cell Signaling Technology), mouse anti-MITF (MS-771-P1, 846 
Thermo Scientific), mouse anti-ȕ-Actin (A5316, Sigma), and mouse anti-Raf-B (sc-5284, Santa 847 
Cruz Biotechnology).  For immunofluorescence staining, cells were fixed and permeabilized 848 
followed by staining with anti-H3K9Me3 antibody (07-442 from Millipore, Billerica, MA) or anti-849 
HP1Jantibody (ab56978 from Abcam).  Cells were then labeled with Alexa Fluor488 donkey 850 
anti-Rabbit secondary Ab or Alexa Fluor568 goat anti-Rabbit secondary antibody (Invitrogen, 851 
Carlsbad, CA) before treated with anti-fade gold mounting medium with DAPI (Invitrogen, 852 
Carlsbad, CA).  Images were examined and processed by a Zeiss LSM 700 confocal 853 
microscope with total 630X magnification.  Representative images are shown.  To measure 854 
H3K9Me3 level by western blotting, total histone was extracted using HCL following a standard 855 
protocol (Abcam) and detected with rabbit anti-Histone H3 (61277, Active Motif) or rabbit anti-856 
Histone H3K9Me3 (ab8898, Abcam) antibody; ratios of H3K9Me3 to total H3 did not correlate 857 
with H3K9Me3 focus formation (Supplementary Fig. 26). 858 
Colony formation assays.  Anchorage-independent growth was assayed with 859 
S¶PHO%5$)9(FHOOV (provided by Dr. Hans Widlund, Dana-Farber Cancer Institute).  Briefly, 860 
2,500 cells were mixed in HAMF12 plus 10% FBS medium containing 0.4% SeaKem LE 861 
agarose from Lonza, and plated on top of the bottom layer with 0.65% agarose prepared in 862 
same HAMF12 medium in 6-well plate.  After the agarose is solidified, each well was covered 863 
with 0.5 mL feeding medium which was refreshed twice a week.  Colonies were counted and 864 
imaged between 3-4 weeks after seeding under a regular microscope with total magnification of 865 
40X. Colonies were counted from three wells of each condition, and significant difference from 866 
the control was assessed by t-test assuming unequal variance. 867 
Chromatin immunoprecipitation of PARP1, H3K4me3, and RNA PolII.  Primary human 868 
melanocytes (HEMn-LP, Invitrogen) were fixed with 0.1% formaldehyde when 80-90% 869 
confluent. About 1 x 107 cells were then sheared by sonication using a Bioruptor (Diagenode) at 870 
high setting for 10 cycles with 20 sec on and 30 sec off.  Chromatin were then purified and 871 
immunoprecipitated following the instructions of Active Motif CHIP-IT high sensitivity kit. 5-10 µg 872 
sheared chromatin were used for each immunoprecipitation with antibodies against 873 
PARP1,46D11 (#9532, Cell Signaling Technology), H3K4me3 (ab8580, Abcam), RNA PolII 874 
CTD (17-672, Millipore), RNA PolII CTD Phospho-Ser5 (ab5408, abcam) or normal rabbit IgGs 875 
(ab46540, Abcam) and normal mouse IgGs (17-672, Millipore). Purified pulled-down DNA was 876 
assayed by SYBR Green qPCR for enrichment of target sites across MITF-M promoter using 877 
primers listed in Supplementary Table 14.  878 
Statistical analyses 879 
All cell-based experiments were repeated at least three times with separate cell cultures, except 880 
for Fig3a (repeated twice), Fig4d-e (six technical replicates), and Fig5d-e (repeated twice). 881 
When a representative set was shown, replicate experiments displayed similar patterns. For all 882 
the plots, individual data points are shown with median or mean, range (maximum and 883 
minimum), and 25 & 75 percentile (where applicable). Statistical method, number of data points, 884 
and number and type of replicates are indicated in each figure legend.  885 
Accession codes 886 
dbGAP Accession: phs000178.v9.p8 887 
dbGaP Accession: phs000424.v6.p1 888 
GEO Accession: GSE60666 889 
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